SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$7.14
Market Cap
$702.93M
52W High
$8.87
52W Low
$6.00
ADV30
1,223,677
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
| Jun 2025 | 0 | — | -41,693,000 | -39,480,000 | 308,292,000 | 138,933,000 | 50,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-171,669,000
Investing CF
$13,767,000
Financing CF
$243,745,000
CapEx
$-1,192,000
Dividends Paid
—
Buybacks
$-14,551,000
EPS Diluted TTM
$-2.01
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,014,512,000
Inventory
—
Receivables
—
ST Investments
$83,581,000
EBIT TTM
$-193,618,000
Pretax Income TTM
$-191,780,000
Interest Exp TTM
$203,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | — | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | — | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | — | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | — | -97,977,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.96
Max Pain — expiry 2026-06-18
max pain strike: $6.00 · spot: $7.36 · call oi: 1,714 · put oi: 1,787
Expected Move to 2026-06-18:
±$1.55
(21.06%) —
implied range
$5.81 –
$8.91
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | $733.24M | $8.88 | — |
| AURA | Aura Biosciences, Inc. | $662.71M | $6.41 | — |
| SANA | Sana Biotechnology, Inc. | $745.82M | $2.68 | — |
| ALLO | Allogene Therapeutics, Inc. | $655.79M | $1.90 | — |
| VOR | Vor Biopharma Inc. | $778.11M | $14.36 | — |
News headlines (Yahoo Finance, 1h cache)
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
2026-06-08 07:00 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-06-01 12:00 · Yahoo
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
2026-05-20 12:36 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
2026-04-28 12:00 · Yahoo
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-19 20:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.